Fax: (215) 627-3925
Adjuvant therapy in stage I carcinoma of the breast†
The influence of multigene analyses and molecular phenotyping
Article first published online: 5 MAR 2012
Copyright © 2012 American Cancer Society
Volume 118, Issue 8, pages 2031–2038, 15 April 2012
How to Cite
Schwartz, G. F., Reis-Fihlo, J., Pusztai, L., Fentiman, I. S., Holland, R., Bartelink, H., Rutgers, E. J. T., Solin, L. J., Palazzo, J. and and the Consensus Committee (2012), Adjuvant therapy in stage I carcinoma of the breast. Cancer, 118: 2031–2038. doi: 10.1002/cncr.27431
The following participated in the 2010 Breast Health International Breast Cancer Consensus Conference, Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses And Molecular Phenotyping, held October 24-26, 2010 in Philadelphia, Pennsylvania: Gordon F. Schwartz, MD, MBA (Jefferson Medical College, Philadelphia, Pa); Harry Bartelink, MD, PhD (The Netherlands Cancer Institute, Amsterdam, the Netherlands); Harold J. Burstein, MD, PhD (Harvard Medical School, Dana-Farber Cancer Institute, Boston, Mass); Blake Cady, MD (Harvard Medical School, Boston, MA);Luigi Cataliotti, MD (University of Florence, Florence, Italy); Ian S. Fentiman, MD (Guys Hospital, London, United Kingdom); Roland Holland, MD (University Hospital Nijmegen, Nigmegen, the Netherlands); Kevin S. Hughes, MD (Harvard Medical School, Massachusetts General Hospital, Boston, MA); Shahla Masood, MD (University of Florida Health Science Center, Jacksonville, Fla); Beryl McCormick, MD (Memorial Sloan-Kettering Cancer Center, New York, NY); Juan A. Palazzo, MD (Jefferson Medical College, Philadelphia, Pa); Peter I. Pressman, MD (New York-Presbyterian Hospital, New York, NY); Jorge Reis-Filho, MD (Chester Beatty Laboratories, London, United Kingdom); Lajos Pusztai, MD (The University of Texas M. D. Anderson Cancer Center, Houston, Tex); Emiel J. T. Rutgers, MD (Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands); Andrew D. Seidman, MD (Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY); Lawrence J. Solin, MD, (Albert Einstein Medical Center, Philadelphia, Pa); and Joseph A. Sparano, MD (Albert Einstein College of Medicine, Bronx, NY).
- Issue published online: 6 APR 2012
- Article first published online: 5 MAR 2012
- Manuscript Accepted: 6 DEC 2011
- Manuscript Revised: 27 NOV 2011
- Manuscript Received: 4 SEP 2011
- 1National Cancer Institute. Clinical Alert. Bethesda, MD. National Cancer Institute; 1988.
- 6Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer. 2002; 94: 2542-2551., , ;
- 10Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors—International Breast Cancer Study Group. J Clin Oncol. 2008; 26: 1404-1410., , , et al.
- 14Classical cyclophosphamide, methotrexate, and fluorouracil is more effective in triple-negative, node-negative breast caner: results from 2 randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol. 2010; 28: 2966-2973., , , et al.